Alpha 1 Antitrypsin Therapy in Patients with Alpha 1 Antitrypsin Deficiency: Perspectives from a Registry Study and Practical Considerations for Self-Administration During the COVID-19 Pandemic

References

• Stoller JK, Aboussouan LS. A review of α1-antitrypsin deficiency. Am J Respir Crit Care Med. 2012;185:246–259.
   PubMed Web of Science ®Google Scholar
• Sharafkhaneh A, Hanania NA, Kim V. Pathogenesis of emphysema: from the bench to the bedside. Proc Am Thorac Soc. 2008;5(4):475–477. doi:10.1513/pats.200708-126ET
   PubMedGoogle Scholar
• Chapman KR, Chorostowska-Wynimko J, Koczulla AR, et al. Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: recent developments and clinical implications. Int J Chron Obstruct Pulmon Dis. 2018;13:419–432. doi:10.2147/COPD.S149429
   PubMed Web of Science ®Google Scholar
• Blanco I, Fernández E, Bustillo EF. Alpha-1-antitrypsin PI phenotypes S and Z in Europe: an analysis of the published surveys. Clin Genet. 2001;60(1):31–41. doi:10.1034/j.1399-0004.2001.600105.x
   PubMed Web of Science ®Google Scholar
• Brantly ML, Wittes JT, Vogelmeier CF, et al. Use of a highly purified α1-antitrypsin standard to establish ranges for the common normal and deficient α1-antitrypsin phenotypes. Chest. 1991;100(3):703–708. doi:10.1378/chest.100.3.703
   PubMed Web of Science ®Google Scholar
• de Serres FJ. Worldwide racial and ethnic distribution of α1-antitrypsin deficiency: summary of an analysis of published genetic epidemiologic surveys. Chest. 2002;122(5):1818–1829. doi:10.1378/chest.122.5.1818
   PubMed Web of Science ®Google Scholar
• Gadek JE, Klein HG, Holland PV, et al. Replacement therapy of alpha 1-antitrypsin deficiency. Reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects. J Clin Invest. 1981;68(5):1158–1165. doi:10.1172/JCI110360
   PubMed Web of Science ®Google Scholar
• Respreeza summary of product characteristics; 2015. Available from: https://www.ema.europa.eu/en/documents/product-information/respreeza-epar-product-information_en.pdf. Accessed October, 2021.
   Google Scholar
• AATD-Registry. Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. Am J Respir Crit Care Med. 1998;158:49–59. doi:10.1164/ajrccm.158.1.9712017
   PubMed Web of Science ®Google Scholar
• Chapman KR, Burdon JGW, Piitulainen E, et al. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;386(9991):360–368. doi:10.1016/S0140-6736(15)60860-1
   PubMed Web of Science ®Google Scholar
• Lieberman J. Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data. Chest. 2000;118(5):1480–1485. doi:10.1378/chest.118.5.1480
   PubMed Web of Science ®Google Scholar
• Seersholm N, Wencker M, Banik N, et al. Does α1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary α1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group. Eur Respir J. 1997;10(10):2260–2263. doi:10.1183/09031936.97.10102260
   PubMed Web of Science ®Google Scholar
• Rahaghi FF, Monk R, Ramakrishnan V, et al. Alpha-1 antitrypsin augmentation therapy improves survival in severely deficient patients with predicted FEV1 between 10% and 60%: a retrospective analysis of the NHLBI alpha-1 antitrypsin deficiency registry. Int J COPD. 2020;15:3193. doi:10.2147/COPD.S263725
   Google Scholar
• Horváth I, Canotilho M, Chlumský J, et al. Diagnosis and management of α1-antitrypsin deficiency in Europe: an expert survey. ERJ Open Res. 2019;5(1):00171–2018. doi:10.1183/23120541.00171-2018
   PubMedGoogle Scholar
• Sandhaus RA, Strange C, Zanichelli A, et al. Improving the lives of patients with alpha-1 antitrypsin deficiency. Int J Chron Obstruct Pulmon Dis. 2020;15:3313–3322. doi:10.2147/COPD.S276773
   PubMed Web of Science ®Google Scholar
• Epping-Jordan J, Pruitt SD, Bengoa R, Wagner EH. Improving the quality of health care for chronic conditions. BMJ Qual Saf. 2004;13:299–305. doi:10.1136/qshc.2004.010744
   Google Scholar
• Gibson PG, Powell H, Wilson A, et al. Self‐management education and regular practitioner review for adults with asthma. Cochrane Database Syst Rev. 2003;(1):CD001117. doi:10.1002/14651858.CD001117
   Google Scholar
• Monninkhof E, van der Valk PP, van der Palen JJ, et al. Self‐management education for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2003;(1):CD002990.doi:10.1002/14651858.CD002990
   PubMedGoogle Scholar
• Bartholomew LK, Czyzewski DI, Parcel GS, et al. Self-management of cystic fibrosis: short-term outcomes of the cystic fibrosis family education program. Health Educ Behav. 1997;24(5):652–666. doi:10.1177/109019819702400511
   PubMed Web of Science ®Google Scholar
• Khair K, Meerabeau L, Gibson F. Self-management and skills acquisition in boys with haemophilia. Health Expect. 2015;18:1105–1113. doi:10.1111/hex.12083
   PubMed Web of Science ®Google Scholar
• Wencker M, Fuhrmann B, Konietzko N, et al. Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor. Chest. 2001;119(3):737–744. doi:10.1378/chest.119.3.737
   PubMed Web of Science ®Google Scholar
• Ficker J, Chapman KR, Turner A, et al. Alpha-1 antitrypsin (A1-PI) treatment slows emphysema progression independent of baseline FEV1. Eur Respir Soc. 2017;50(suppl 61):OA3416.
   Google Scholar
• McElvaney NG, Burdon J, Holmes M, et al. Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE). Lancet Respir Med. 2017;5(1):51–60. doi:10.1016/S2213-2600(16)30430-1
   PubMed Web of Science ®Google Scholar
• Administration FFaD. Chronic obstructive pulmonary disease: use of the St. George’s respiratory questionnaire as a PRO assessment tool. Guidance for Industry; 2018. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chronic-obstructive-pulmonary-disease-use-st-georges-respiratory-questionnaire-pro-assessment-tool. Accessed October, 2021.
   Google Scholar
• Stockley RA, Edgar RG, Starkey S, et al. Health status decline in α-1 antitrypsin deficiency: a feasible outcome for disease modifying therapies? Respir Res. 2018;19(1):137. doi:10.1186/s12931-018-0844-6
   PubMedGoogle Scholar
• Ellis P, Holm K, Choate R, et al. Comparison of outcomes in augmentation naïve and augmented patients with alpha-1 antitrypsin deficiency related lung disease. Eur Respir J. 2019;54:PA3383.
   Web of Science ®Google Scholar
• Sandhaus R, Ellis P, Holm K, et al. Augmentation therapy for alpha-1 antitrypsin deficiency: improved survival and quality of life compared to matched augmentation naive controls followed for up to 15 years. A92 medical and interventional management of obstructive lung disease. Am J Respir Crit Care Med. 2020;201:A2486.
   Web of Science ®Google Scholar
• Chorostowska-Wynimko J, Barrecheguren M, Ferrarotti I, et al. New patient-centric approaches to the management of alpha-1 antitrypsin deficiency. Int J COPD. 2020;15:345–355. doi:10.2147/COPD.S234646
   Google Scholar
• Wilke A, Grohé C. Prospective evaluation of clinical parameters of AAT patients with i. v. prolastin therapy in a homecare setting. Pneumologie. 2013;67:545–550.
   PubMedGoogle Scholar
• Annunziata A, Lanza M, Coppola A, et al. Alpha-1 antitrypsin deficiency: home therapy. Front Pharmacol. 2021;12:575402. doi:10.3389/fphar.2021.575402
   PubMed Web of Science ®Google Scholar
• Symons C, Rossi O, Magerl M, et al. Practical approach to self-administration of intravenous C1-INH concentrate: a nursing perspective. Int Arch Allergy Immunol. 2013;161(Suppl s1):17–20. doi:10.1159/000351236
   PubMedGoogle Scholar
• Craig TJ. Recent advances in hereditary angioedema self-administration treatment: summary of an international hereditary angioedema expert meeting. Int Arch Allergy Immunol. 2013;161(s1):26. doi:10.1159/000351241
   PubMedGoogle Scholar
• Tonna A, Anthony G, Tonna I, et al. Home self-administration of intravenous antibiotics as part of an outpatient parenteral antibiotic therapy service: a qualitative study of the perspectives of patients who do not self-administer. BMJ Open. 2019;9(1):e027475. doi:10.1136/bmjopen-2018-027475
   PubMed Web of Science ®Google Scholar
• Boysen HB, Bouillet L, Aygören-Pürsün E. Challenges of C1-inhibitor concentrate self-administration. Int Arch Allergy Immunol. 2013;161(Suppl 1):21–25. doi:10.1159/000351238
   PubMed Web of Science ®Google Scholar
• Bygum A, Andersen KE, Mikkelsen CS. Self-administration of intravenous C1-inhibitor therapy for hereditary angioedema and associated quality of life benefits. Eur J Dermatol. 2009;19(2):147–151. doi:10.1684/ejd.2008.0603
   PubMed Web of Science ®Google Scholar
• Stiver HG, Trosky SK, Cote DD, Oruck JL. Self-administration of intravenous antibiotics: an efficient, cost-effective home care program. Can Med Assoc J. 1982;127:207–211.
   PubMed Web of Science ®Google Scholar
• Boyd BS. Alpha 1 antitrypsin therapy: a satisfaction survey of individuals self-administering. A46 topics in alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2018;197:A1758.
   Web of Science ®Google Scholar
• Zanichelli A, Azin GM, Cristina F, et al. Safety, effectiveness, and impact on quality of life of self-administration with plasma-derived nanofiltered C1 inhibitor (Berinert®) in patients with hereditary angioedema: the SABHA study. Orphanet J Rare Dis. 2018;13(1):1–8. doi:10.1186/s13023-018-0797-3
   PubMedGoogle Scholar
• Longhurst HJ, Farkas H, Craig T, et al. HAE international home therapy consensus document. Allergy Asthma Clin Immunol. 2010;6(1):1–7. doi:10.1186/1710-1492-6-22
   PubMedGoogle Scholar
• Ochs HD, Gupta S, Kiessling P, et al. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol. 2006;26(3):265–273. doi:10.1007/s10875-006-9021-7
   PubMed Web of Science ®Google Scholar
• Kayley J, Berendt AR, Snelling MJM, et al. Safe intravenous antibiotic therapy at home: experience of a UK based programme. J Antimicrob Chemother. 1996;37(5):1023–1029. doi:10.1093/jac/37.5.1023
   PubMed Web of Science ®Google Scholar
• Wencker M, Banik N, Buhl R, et al. Long-term treatment of alpha1-antitrypsin deficiency-related pulmonary emphysema with human alpha1-antitrypsin. Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL)-alpha1-AT-study group. Eur Respir J. 1998;11:428–433. doi:10.1183/09031936.98.11020428
   PubMed Web of Science ®Google Scholar
• Vilasuso M, Barnett N. Self-medication – take it or leave it. Pharmaceutical J. 2007;278:72.
   Google Scholar
• Patient Self Administration of Intravenous (IV) Antibiotics at Home. West Suffolk NHS Foundation Trust Policy. Document Ref. No: PP(19)319; 2019.
   Google Scholar
• Self-management of diabetes in hospital. NHS Diabetes; 2012. Available from: https://www.diabetes.org.uk/professionals/position-statements-reports/specialist-care-for-children-and-adults-and-complications/self-management-of-diabetes-in-hospital. Accessed October, 2021.
   Google Scholar
• Frid AH, Kreugel G, Grassi G, et al. New insulin delivery recommendations. Mayo Clin Proc. 2016;91:1231–1255.
   PubMed Web of Science ®Google Scholar
• Sandhaus RA, Turino G, Brantly ML, et al. The diagnosis and management of alpha-1 antitrypsin deficiency in the adult. Chronic Obstr Pulm Dis. 2016;3:668–682.
   PubMed Web of Science ®Google Scholar
• American Thoracic Society/European Respiratory Society Statement. European respiratory society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003;168:818–900. doi:10.1164/rccm.168.7.818
   PubMed Web of Science ®Google Scholar
• Gaeckle NT, Stephenson L, Reilkoff RA. Alpha-1 antitrypsin deficiency and pregnancy. COPD. 2020;17(3):326–332. doi:10.1080/15412555.2020.1754778
   PubMedGoogle Scholar
• Prolastin summary of product characteristics 2021. Available from: https://www.hpra.ie/img/uploaded/swedocuments/Licence_PA1405-002-001_23062021102832.pdf. Accessed October, 2021.
   Google Scholar
• Aralast summary of product characteristics; 2018. Available from: https://myhealthbox.eu/en/vi6ew/2419858/c651c6b14aef987a406b2fb4ce168fbf/leaflet. Accessed October, 2021.
   Google Scholar
• Glassia highlights of prescribing information. Available from: https://www.fda.gov/media/78773/download. Accessed October, 2021.
   Google Scholar
• Rizk C, Karsh J, Santucci S, et al. Self-administration of intravenous C1 esterase inhibitor in hereditary angioedema. CMAJ. 2013;185(9):791–792. doi:10.1503/cmaj.121364
   PubMed Web of Science ®Google Scholar
• Guidelines for the management of Hemophilia; 2012. Available from: www.wfh.org. Accessed October, 2021.
   Google Scholar
• Administration ENGfI. SCIG Self-Administration at Home – In Adults. 2019. Immunodeficiences INGf, ed. 64–76.
   Google Scholar
• Guideline on good pharmacovigilance practices (GVP); 2012. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-good-pharmacovigilance-practices-module-vi-management-reporting-adverse-reactions_en.pdf. Accessed October, 2021.
   Google Scholar
• European Medicines Agency. How to report a side effect; 2020. Available from: http://www.adrreports.eu/docs/ADR_reporting_FINAL_EN.pdf. Accessed October, 2021.
   Google Scholar
• O’Brien ME, Fee L, Browne N, et al. Activation of complement component 3 is associated with airways disease and pulmonary emphysema in alpha-1 antitrypsin deficiency. Thorax. 2020;75(4):321–330. doi:10.1136/thoraxjnl-2019-214076
   PubMed Web of Science ®Google Scholar
• McElvaney OJ, Carroll TP, Franciosi AN, et al. Consequences of abrupt cessation of alpha 1-antitrypsin replacement therapy. N Engl J Med. 2020;382(15):1478–1480. doi:10.1056/NEJMc1915484
   PubMed Web of Science ®Google Scholar
• Fischer H-P, Ortiz-Pallardó ME, Ko Y, et al. Chronic liver disease in heterozygous α1-antitrypsin deficiency PiZ. J Hepatol. 2000;33(6):883–892. doi:10.1016/S0168-8278(00)80119-1
   PubMed Web of Science ®Google Scholar
• Hill AT, Campbell E, Bayley D, et al. Evidence for excessive bronchial inflammation during an acute exacerbation of chronic obstructive pulmonary disease in patients with α1-antitrypsin deficiency (PiZ). Am J Respir Crit Care Med. 1999;160(6):1968–1975. doi:10.1164/ajrccm.160.6.9904097
   PubMed Web of Science ®Google Scholar
• Yang C, Chapman KR, Wong A, et al. α1-antitrypsin deficiency and the risk of COVID-19: an urgent call to action. Lancet Respir Med. 2021;9(4):337–339. doi:10.1016/S2213-2600(21)00018-7
   PubMed Web of Science ®Google Scholar
• Bai X, Hippensteel J, Leavitt A, et al. Hypothesis: alpha-1-antitrypsin is a promising treatment option for COVID-19. Med Hypotheses. 2021;146:110394. doi:10.1016/j.mehy.2020.110394
   PubMed Web of Science ®Google Scholar
• Azouz NP, Klingler AM, Callahan V, et al. Alpha 1 antitrypsin is an inhibitor of the SARS-CoV-2-priming protease TMPRSS2. Pathog Immun. 2021;6:55
   PubMedGoogle Scholar
• Tanash HA, Ekström M, Wagner P, et al. Cause-specific mortality in individuals with severe alpha 1-antitrypsin deficiency in comparison with the general population in Sweden. Int J Chron Obstruct Pulmon Dis. 2016;11:1663–1669. doi:10.2147/COPD.S109173
   PubMed Web of Science ®Google Scholar
• Zhang X, Yang X, Jiao H, et al. Coagulopathy in patients with COVID-19: a systematic review and meta-analysis. Aging. 2020;12(24):24535–24551. doi:10.18632/aging.104138
   PubMedGoogle Scholar
• McElvaney OJ, McEvoy NL, McElvaney OF, et al. Characterization of the inflammatory response to severe COVID-19 illness. Am J Respir Crit Care Med. 2020;202:812–821. doi:10.1164/rccm.202005-1583OC
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Chorostowska-Wynimko J, Ferrarotti I, et al. The European Alpha-1 Research Collaboration (EARCO): a new ERS clinical research collaboration to promote research in alpha-1 antitrypsin deficiency. Eur Respir J. 2019;53(2):1900138. doi:10.1183/13993003.00138-2019
   PubMed Web of Science ®Google Scholar
• AlphaNet. Available from: https://www.alphanet.org/. Accessed October, 2021.
   Google Scholar
• Zádori N, Váncsa S, Farkas N, et al. The negative impact of comorbidities on the disease course of COVID-19. Intensive Care Med. 2020;46(9):1784–1786. doi:10.1007/s00134-020-06161-9
   PubMed Web of Science ®Google Scholar
• Alqahtani JS, Oyelade T, Aldhahir AM, et al. Prevalence, severity and mortality associated with COPD and smoking in patients with COVID-19: a rapid systematic review and meta-analysis. PLoS One. 2020;15(5):e0233147. doi:10.1371/journal.pone.0233147
   PubMed Web of Science ®Google Scholar
• Campos MA, Kueppers F, Stocks JM, et al. Safety and pharmacokinetics of 120 mg/kg versus 60 mg/kg weekly intravenous infusions of alpha-1 proteinase inhibitor in alpha-1 antitrypsin deficiency: a multicenter, randomized, double-blind, crossover study (SPARK). COPD. 2013;10(6):687–695. doi:10.3109/15412555.2013.800852
   PubMedGoogle Scholar
• Greulich T, Chlumsky J, Wencker M, et al. Safety of biweekly α1-antitrypsin treatment in the RAPID programme. Eur Respir J. 2018;52(5):1800897. doi:10.1183/13993003.00897-2018
   PubMed Web of Science ®Google Scholar
• Ritzmann F, Chitirala P, Krüger N, et al. Therapeutic application of alpha-1-antitrypsin in COVID-19. Am J Respir Crit Care Med. 2021. doi:10.1164/rccm.202104-0833LE
   PubMed Web of Science ®Google Scholar
• Clinical trials.gov. NCT04385836. Available from: https://clinicaltrials.gov/ct2/show/NCT04385836?term=COVID-19+antitrypsin+therapy&draw=2&rank=6. Accessed October, 2021.
   Google Scholar
• EU Clinical Trial Register. 2020-001391-15. Available from: https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001391-15/IE. Accessed October, 2021.
   Google Scholar
• Clinical trials.gov. NCT04495101. Available from: https://clinicaltrials.gov/ct2/show/NCT04495101?term=NCT04495101&draw=2&rank=1. Accessed October, 2021.
   Google Scholar
• Clinical trials.gov. NCT04547140. Available from: https://clinicaltrials.gov/ct2/show/NCT04547140?term=Alpha+1+in+COVID-19&draw=2&rank=1. Accessed October, 2021.
   Google Scholar